Olvi-Vec + Chemotherapy for Ovarian Cancer
(OnPrime Trial)
Trial Summary
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot participate if you have received chemotherapy, radiotherapy, or other anti-cancer biologic therapies within 4 weeks prior to the planned treatment, or if you are receiving immunosuppressive therapy or steroids above a certain dose.
Research shows that adding bevacizumab (a drug that stops the growth of new blood vessels) to standard chemotherapy can improve the time patients live without their cancer getting worse, although it doesn't increase overall survival. This suggests that combining bevacizumab with chemotherapy might help control ovarian cancer for a longer period.
12345Bevacizumab, a component of the treatment, has been studied extensively and is generally considered safe for ovarian cancer, though it can cause side effects like high blood pressure, bleeding, and delayed wound healing. These side effects are usually manageable by doctors. The safety of Olvi-Vec specifically is not detailed in the provided research.
26789The Olvi-Vec + Chemotherapy treatment is unique because it combines a novel oncolytic virus therapy (Olvimulogene Nanivacirepvec) with standard chemotherapy and bevacizumab, potentially offering a new mechanism of action by using a virus to target cancer cells, which is different from traditional chemotherapy or bevacizumab alone.
14101112Eligibility Criteria
This trial is for women with ovarian cancer that's resistant to platinum-based treatments. They should have had at least three prior systemic therapies, a life expectancy of over six months, and no major health issues that would interfere with the treatment. Participants must not have had recent surgeries or other cancers in the last three years, among other criteria.Inclusion Criteria
Exclusion Criteria
Participant Groups
- Colorectal cancer
- Breast cancer
- Non-small cell lung cancer
- Renal cell carcinoma
- Ovarian cancer
- Colorectal cancer
- Non-small cell lung cancer
- Glioblastoma
- Renal cell carcinoma
- Cervical cancer
- Ovarian cancer
- Colorectal cancer
- Non-small cell lung cancer
- Breast cancer
- Renal cell carcinoma
- Ovarian cancer
- Colorectal cancer
- Non-small cell lung cancer
- Breast cancer
- Renal cell carcinoma
- Ovarian cancer